Intellia Therapeutics Inc. (NTLA) has exhibited robust bullish price action in recent months. Shares have surged approximately 25% over the past month and 8.5% in the last week, reflecting heightened buying interest. The stock has decisively moved above its 200-day simple moving average, confirming a shift to a longer-term uptrend following a period of consolidation near lower levels around $6-$7 earlier in the year. This upward trajectory aligns with broader strength in the gene editing sector, supported by increasing volume during advances.
NTLA trades significantly above its key moving averages, underscoring bullish trend continuation. The 50-day simple moving average sits around $13.50-$15.24, with the 100-day at approximately $12.20-$14.50, and the 200-day near $13.10-$13.77. All major MAs—ranging from 5-day to 200-day—generate buy signals, with 12 buy indications across simple and exponential averages. The golden cross, where the 50-day MA crossed above the 200-day in early March, further bolsters the positive structure.
Momentum remains favorable, with the RSI(14) reading around 57-62, placing it in buy territory without entering overbought extremes. The MACD(12,26) shows a positive value of 0.33, confirming bullish divergence and upward histogram expansion. However, short-term stochastics (9-day) hover in the 81-87% range, signaling overbought conditions that could lead to minor consolidations. ADX at 30 indicates a strengthening trend, with +DI dominating -DI.
Traders are eyeing immediate support at pivot S1 near $15.90-$16.07 and the 20-day MA around $14-$16. Deeper support aligns with the 50-day MA at $13.50 and prior lows near $13. Resistance clusters at pivot R1 $16.42, R2 $16.59, and R3 $16.68, with potential extension toward prior highs around $28 if breached. Classic pivot point stands at $16.33, acting as a neutral battleground.
Trading volume has supported the rally, averaging 3.5-4 million shares daily, with spikes accompanying recent gains of over 20% in three weeks. Elevated participation confirms conviction behind the upmove, though average true range of 0.90 (5.5%) highlights ongoing volatility consistent with biotech sector dynamics.
Tickeron’s AI Daily Buy/Sell Signals leverage artificial intelligence to scrutinize vast arrays of market data, technical indicators, and historical price patterns, generating actionable buy or sell signals for stocks like NTLA. These signals draw from trend recognition, momentum shifts, and recurring chart behaviors to pinpoint potential entry and exit opportunities. Traders rely on them to validate trend strength, time trades amid volatility, and enhance decision-making with data-driven insights rather than guesswork. Explore these signals to integrate AI-powered analysis into your trading strategy.
Market participants will monitor price behavior around the $16.30-$16.70 resistance cluster for breakout confirmation, with failure potentially testing support at $15.90 and the 50-day MA. Sustained trades above the 20-day MA would reinforce the uptrend, while RSI divergence or stochastic unwind could signal pauses. Volume trends and MACD histogram will be critical for assessing momentum sustainability amid high beta exposure.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To NTLA | 1D Price Change % | ||
|---|---|---|---|---|
| NTLA | 100% | -3.17% | ||
| VCYT - NTLA | 69% Closely correlated | +1.13% | ||
| BEAM - NTLA | 59% Loosely correlated | -6.56% | ||
| EDIT - NTLA | 57% Loosely correlated | -1.61% | ||
| CRSP - NTLA | 56% Loosely correlated | -0.68% | ||
| AXON - NTLA | 55% Loosely correlated | +5.61% | ||
More | ||||